Molecular Partners Ag (MOLN) EBITDA Margin (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly EBITDA Margin of 97.86% for Q1 2026, up 1306.0% year-over-year from 6.96% in Q1 2025, and down 100.07% quarter-over-quarter from 132831.87% in Q4 2025.
Molecular Partners Ag (MOLN) EBITDA Margin (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EBITDA Margin for 7 consecutive years, with 97.86% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 1306.0% year-over-year to 97.86%; the TTM figure through Mar 2026 stood at 2595731.22% (up 259574138.0% YoY), while the FY2025 annual figure was 100041308.09%, up 112429869191.0% from the prior year.
- EBITDA Margin slipped to 97.86% in Q1 2026 per MOLN's latest filing, from 132831.87% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1096820.95% in Q4 2024 and bottomed at 1030045132.17% in Q2 2024.
- Historically, EBITDA Margin has averaged 60524702.08% across 5 years, with a median of 97.86% in 2026.
- Annual changes were most pronounced in 2024 — EBITDA Margin sank 2000000000 bps — and 2025, when it jumped 2000000000 bps.
- Molecular Partners Ag's EBITDA Margin stood at 82.56% in 2022, then sank by 1112 bps to 835.86% in 2023, then surged by 131320 bps to 1096820.95% in 2024, then tumbled by 88 bps to 132831.87% in 2025, then plunged by 100 bps to 97.86% in 2026.
- Business Quant data shows MOLN's EBITDA Margin at 97.86% in Q1 2026, 132831.87% in Q4 2025, and 99.57% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.86% |
| Dec 31, 2025 | 132,831.87% |
| Sep 30, 2025 | -99.57% |
| Jun 30, 2025 | -100,000.00% |
| Mar 31, 2025 | -110.92% |
| Dec 31, 2024 | 1,096,820.95% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | -1,030,045,132.17% |
| Mar 31, 2024 | -413.99% |
| Dec 31, 2023 | -835.86% |
| Sep 30, 2023 | -450.61% |
| Jun 30, 2023 | -3,827.23% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 82.56% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 1,297.44% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.80% |
| Sep 30, 2021 | -352.11% |
| Jun 30, 2021 | 3.47% |